|
Not yet recruiting
|
NCT06409936 -
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
|
Phase 2 |
|
Terminated
|
NCT04006847 -
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
|
Phase 1/Phase 2 |
|
Not yet recruiting
|
NCT06368414 -
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
|
Phase 2 |
|
Active, not recruiting
|
NCT04126681 -
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
|
Phase 2 |
|
Not yet recruiting
|
NCT05543161 -
"Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"
|
|
|
Recruiting
|
NCT05638763 -
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
|
Phase 2 |
|
Recruiting
|
NCT03610971 -
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
|
Phase 2 |
|
Completed
|
NCT03332511 -
Efficacy and Safety of Nilotinib in CML-CP
|
Phase 4 |
|
Active, not recruiting
|
NCT06233890 -
The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
|
|
|
Completed
|
NCT03882281 -
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
|
Phase 1 |
|
Recruiting
|
NCT03459534 -
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
|
Phase 3 |
|
Completed
|
NCT03885830 -
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
|
|
|
Active, not recruiting
|
NCT04147533 -
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia
|
Phase 2 |
|
Recruiting
|
NCT03942094 -
Nilotinib for First-line Newly Diagnosed CML-CP Patients
|
Phase 3 |
|
Recruiting
|
NCT05311943 -
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
|
Phase 3 |
|
Active, not recruiting
|
NCT04160546 -
Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)
|
Phase 2 |
|
Recruiting
|
NCT04677439 -
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
|
Phase 4 |
|
Active, not recruiting
|
NCT03722420 -
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
|
Phase 3 |
|
Not yet recruiting
|
NCT06163430 -
CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
|
Phase 1 |
|
Completed
|
NCT02977312 -
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan
|
N/A |